Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
WGS GeneDx Holdings Corp
- Stocks
- Healthcare
- NASDAQ: WGS
Price (delayed)
$56.36
Market cap
$1.61B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.41
Enterprise value
$1.62B
Sema4 is a patient-centered health intelligence company dedicated to advancing healthcare through data-driven insights. Sema4 is transforming healthcare by applying AI and machine learning to multidimensional, longitudinal clinical and genomic
Highlights
The gross profit has surged by 92% year-on-year and by 11% since the previous quarter
GeneDx Holdings's EPS has surged by 73% YoY and by 27% QoQ
WGS's quick ratio is down by 10% since the previous quarter but it is up by 5% year-on-year
Key stats
What are the main financial stats of WGS
Market
Valuations
Earnings
Shares outstanding
28.53M
Market cap
$1.61B
Enterprise value
$1.62B
Price to earnings (P/E)
N/A
Price to book (P/B)
6.15
Price to sales (P/S)
4.81
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.92
Revenue
$330.14M
Gross profit
$215.46M
Operating income
-$14.1M
Net income
-$38.58M
EBIT
-$35.32M
EBITDA
-$12.93M
Free cash flow
-$13.08M
Per share
Balance sheet
Liquidity
EPS
-$1.41
EPS diluted
-$1.41
Free cash flow per share
-$0.46
Book value per share
$9.17
Revenue per share
$11.73
TBVPS
$10.35
Total assets
$446.43M
Total liabilities
$189.03M
Debt
$114.84M
Equity
$257.41M
Working capital
$156.28M
Debt to equity
0.45
Current ratio
3.25
Quick ratio
2.95
Net debt/EBITDA
-1.17
Margins
Efficiency
Dividend
EBITDA margin
-3.9%
Gross margin
65.3%
Net margin
-11.7%
Operating margin
-4.3%
Return on assets
-9.3%
Return on equity
-17.1%
Return on invested capital
-15.4%
Return on capital employed
-9.4%
Return on sales
-10.7%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
WGS stock price
How has the GeneDx Holdings stock price performed over time
Intraday
-1.71%
1 week
-9.56%
1 month
-34.43%
1 year
192.48%
YTD
-26.67%
QTD
-36.36%
Financial performance
How have GeneDx Holdings's revenue and profit performed over time
Revenue
$330.14M
Gross profit
$215.46M
Operating income
-$14.1M
Net income
-$38.58M
Gross margin
65.3%
Net margin
-11.7%
The operating margin has soared by 93% YoY and by 43% from the previous quarter
The gross profit has surged by 92% year-on-year and by 11% since the previous quarter
The operating income has soared by 89% YoY and by 39% from the previous quarter
WGS's net margin has surged by 81% year-on-year and by 32% since the previous quarter
Price vs fundamentals
How does WGS's price correlate with its fundamentals
Growth
What is GeneDx Holdings's growth rate over time
Valuation
What is GeneDx Holdings stock price valuation
P/E
N/A
P/B
6.15
P/S
4.81
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.92
GeneDx Holdings's EPS has surged by 73% YoY and by 27% QoQ
The stock's P/B is 27% less than its 5-year quarterly average of 8.4 and 10% less than its last 4 quarters average of 6.8
The company's equity rose by 24% YoY and by 5% QoQ
The stock's P/S is 109% above its 5-year quarterly average of 2.3 but 11% below its last 4 quarters average of 5.4
WGS's revenue is up by 49% year-on-year and by 8% since the previous quarter
Efficiency
How efficient is GeneDx Holdings business performance
GeneDx Holdings's return on sales has surged by 83% YoY and by 34% QoQ
The ROIC has soared by 80% YoY and by 31% from the previous quarter
The ROA has soared by 71% year-on-year and by 28% since the previous quarter
The ROE has soared by 69% YoY and by 30% from the previous quarter
Dividends
What is WGS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for WGS.
Financial health
How did GeneDx Holdings financials performed over time
WGS's total assets is 136% greater than its total liabilities
WGS's total assets is up by 13% year-on-year and by 6% since the previous quarter
The current ratio has declined by 10% since the previous quarter
WGS's debt is 55% smaller than its equity
The company's equity rose by 24% YoY and by 5% QoQ
The debt to equity has declined by 21% year-on-year and by 4.3% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.